CVS Health Stock Soars 6.6% Ahead of Q1 Earnings

CVS Health's stock surged 6.6% in pre-market trading on May 1, 2025, ahead of its Q1 earnings report scheduled for release before the market opens.

CVS Health is anticipated to report a 5.4% year-on-year increase in revenue to $93.18 billion, with adjusted earnings expected to rise 27.5% to $1.67 per share. Analysts are optimistic about the company's ability to meet or exceed these estimates, citing improvements in Aetna's performance and strong demand for specialty drugs in the PBM segment.

Leerink Partners and Morgan Stanley have both reiterated their positive outlook on CVS Health, with Leerink boosting its price target to $79.00 and Morgan Stanley raising its target to $80.00. However, Baird analysts expect the company to maintain a conservative stance on guidance due to potential economic headwinds.

On TipRanks, CVS Health has a Strong Buy consensus based on 17 Buy and 3 Hold ratings, with the highest price target set at $90. The company's Healthcare Benefits segment is also expected to show improved results in the first quarter of 2025, following a challenging fourth quarter.